Design and construction of a magnetic targeting pro-coagulant protein for embolic therapy of solid tumors

References

• Vaidya S, Tozer KR, Chen J. An overview of embolic agents[J]. Semin Intervent Radiol. 2008;25(03):204–215.
   PubMedGoogle Scholar
• Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies[J]. Cardiovasc Intervent Radiol. 2007;30(1):6–25.
   PubMed Web of Science ®Google Scholar
• Li S, Jiang Q, Liu S, et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo[J]. Nat Biotechnol. 2018; 36(3):258–264.
   PubMed Web of Science ®Google Scholar
• Muller YA, Ultsch MH, de Vos AM. The crystal structure of the extracellular domain of human tissue factor refined to 1.7 angstrom resolution[J]. J Mol Biol. 1996;256(1):144–159.
   PubMed Web of Science ®Google Scholar
• Drozdowska J. [Tissue factor in endothelial cells-its structure and function according to the current literature]. Postepy Biochem. 2012;58(3):273–280.
   PubMedGoogle Scholar
• Huang X, Molema G, King S. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature[J]. Science. 1997;275(5299):547–550.
   PubMed Web of Science ®Google Scholar
• Ruf W, Rehemtulla A, Morrissey JH, et al. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem. 1991;266(24):16256–16266.
   PubMedGoogle Scholar
• Hu P, Yan J, Sharifi J, et al. Comparison of three different targeted Tissue Factor fusion proteins for inducing tumor vessel thrombosis[J]. Cancer Res. 2003;63(16):5046–5053.
   PubMed Web of Science ®Google Scholar
• Kessler T, Bieker R, Padró T, et al. Inhibition of tumor growth by RGD Peptide-Directed delivery of truncated tissue factor to the tumor vasculature[J]. Clin Cancer Res. 2005;11(17):6317–6324.
   PubMed Web of Science ®Google Scholar
• Persigehl T, Ring J, Bremer C, et al. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF–NGR using multi-modal imaging[J]. Angiogenesis. 2014;17(1):235–246.
   PubMed Web of Science ®Google Scholar
• Shi Q, Zhang Y, Liu S, et al. Specific tissue factor delivery using a tumor-homing peptide for inducing tumor infarction[J]. Biochem Pharmacol. 2018;156:501–510.
   PubMed Web of Science ®Google Scholar
• Zou M, Samiullah M, Xu P, et al. Construction of novel procoagulant protein targeting Neuropilin-1 on tumor vasculature for tumor embolization therapy[J]. J Drug Target. 2019;27(8):885–895.
   PubMed Web of Science ®Google Scholar
• Kurschat P, Bielenberg D, Rossignol-Tallandier M, et al. Neuron restrictive silencer factor NRSF/REST is a transcriptional repressor of neuropilin-1 and diminishes the ability of semaphorin 3A to inhibit keratinocyte migration[J]. J Biol Chem. 2006;281(5):2721–2729.
   PubMed Web of Science ®Google Scholar
• Latil A, Bièche I, Pesche S, et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms[J]. Int J Cancer. 2000;89(2):167–171.
   PubMed Web of Science ®Google Scholar
• Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells[J]. Cancer Res. 2001;61(15):5736–5740.
   PubMed Web of Science ®Google Scholar
• Fakhari M, Pullirsch D, Abraham D, et al. Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma.[J]. Cancer. 2002;94(1):258–263.
   PubMed Web of Science ®Google Scholar
• Bwc T, Volpert M, Ratther E, et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality[J]. Oncogene. 2017;36(24):3417–3427.
   PubMed Web of Science ®Google Scholar
• Jia H, Bagherzadeh A, Hartzoulakis B, et al. Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling.[J]. J Biol Chem. 2006;281(19):13493–13502.
   PubMed Web of Science ®Google Scholar
• Shi Z, Neoh KG, Kang ET, et al. (Carboxymethyl)chitosan-Modified superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of stem cells[J]. ACS Appl Mater Interfaces. 2009;1(2):328–335.
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Das M, Mishra D, et al. Folatereceptor targeted, carboxymethyl chitosan functionalized iron oxide nanoparticles: a novel ultradispersed nanoconjugates for bimodal imaging[J]. Nanoscale. 2011;3(4):1653–1662.
   PubMed Web of Science ®Google Scholar
• Dusza A, Wojtyniak M, Nedelko N, et al. Magnetic behavior of O-Carboxymethylchitosan bounded with iron oxide particles[J]. IEEE Trans Magn. 2010;46(2):459–462.
   Web of Science ®Google Scholar
• Arias LS, Pessan JP, Vieira APM, et al. Iron oxide nanoparticles for biomedical applications: a perspective on synthesis, drugs, antimicrobial activity, and toxicity[J]. Antibiotics. 2018;7(2):46–78.
   Google Scholar
• Xu J, Du Y, Liu XJ, et al. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy[J]. Pharmacol Res. 2017;126:66–76.
   PubMed Web of Science ®Google Scholar
• Xu J, Liu XJ, Li L, et al. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy[J]. Oncotarget. 2015;6(28):26322–26334.
   PubMedGoogle Scholar
• Meng H, Zhang Z, Zhao F, et al. Orthogonal optimization design for preparation of Fe3O4 nanoparticles via chemical coprecipitation[J]. Appl Surf Sci. 2013;280(8):679–685.
   Google Scholar
• Mikhaylova M, Kim DK, Berry CC, et al. BSA immobilization on Amine-Functionalized superparamagnetic iron oxide nanoparticles[J]. Chem Mater. 2004;16(12):2344–2354.
   Web of Science ®Google Scholar
• Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner.[J]. Cancer Res. 2007;67(4):1555–1562.
   PubMed Web of Science ®Google Scholar
• Miao HQ, Soker S, Feiner L, et al. Neuropilin-1 mediates Collapsin-1/Semaphorin III inhibition of endothelial cell motility: functional competition of Collapsin-1 and vascular endothelial growth factor-165[J]. J Cell Biol. 1999;146(1):233–242.
   PubMed Web of Science ®Google Scholar
• Pan Q, Chathery Y, Wu Y, et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting[J]. J Biol Chem. 2007;282(33):24049–24056.
   PubMed Web of Science ®Google Scholar
• Thomas N, Bechet D, Becuwe P, et al. Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo[J]. J Photochem Photobiol B. 2009;96(2):101–108.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Tsao N, Chou HH, et al. Release of FITC-BSA from poly(l-lactic acid) microspheres analysis using flow cytometry.[J]. Colloids Surf B Biointerfaces. 2012;89(1):271–276.
   PubMedGoogle Scholar
• Hische EA, Tutuarima JA, van der Helm HJ. Spectrophotometry of tissue thromboplastin in cerebrospinal fluid[J]. Clin Chem. 1981;27(8):1427–1430.
   PubMed Web of Science ®Google Scholar
• Sun FX, Tang ZY, Liu KD, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues[J]. Int J Cancer. 1996;66(2):239–243.
   PubMed Web of Science ®Google Scholar
• Zhao GJ, Xu LX, Chu ES, et al. Establishment of an orthotopic transplantation tumor model of hepatocellular carcinoma in mice.[J]. World J Gastroenterol. 2012;18(47):7087–7092.
   PubMed Web of Science ®Google Scholar
• Schmitz V, Tirado-Ledo L, Tiemann K, et al. Establishment of an orthotopic tumour model for hepatocellular carcinoma and non-invasive in vivo tumour imaging by high resolution ultrasound in mice[J]. J Hepatol. 2004;40(5):787–791.
   PubMed Web of Science ®Google Scholar
• Sitthichai S, Pilapong C, Thongtem T, et al. CMC-coated Fe 3 O 4 nanoparticles as new MRI probes for hepatocellular carcinoma[J]. Appl Surf Sci. 2015;356:972–977.
   Web of Science ®Google Scholar
• Hong RY, Feng B, Chen LL, et al. Synthesis, characterization and MRI application of dextran-coated Fe3O4 magnetic nanoparticles[J]. Biochem Eng J. 2008;42(3):290–300.
   Web of Science ®Google Scholar
• Burrows FJ, Thorpe PE. Vascular targeting-a new approach to the therapy of solid tumors]. Pharmacol Ther. 1994;64(1):155–174.
   PubMed Web of Science ®Google Scholar
• Tie J, Desai J.Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog. 2012;17(1):51–67. 22471664 doi:10.1615/critrevoncog.v17.i1.50.
   PubMedGoogle Scholar
• Wick W, Platten M, Wick A, et al. Editor's choice: Current status and future directions of anti-angiogenic therapy for gliomas[J]. Neuro Oncol. 2016;18(3):315–328.
   PubMed Web of Science ®Google Scholar
• Jayson G C, Kerbel R, Ellis L M, et al. Antiangiogenic therapy in oncology: current status and future directions. The Lancet. 2016;388(10043):518–529. doi:10.1016/S0140-6736(15)01088-0.
   PubMed Web of Science ®Google Scholar
• Lübbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting.[J]. J Surg Res. 2001;95(2):200–206.
   PubMed Web of Science ®Google Scholar
• Krukemeyer MG, Wagner W, Jakobs M, et al. Tumor regression by means of magnetic drug targeting[J]. Nanomedicine. 2009;4(8):875–882.
   PubMed Web of Science ®Google Scholar
• Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-Analysis of randomized controlled trials1[J]. Radiology. 2002;224(1):47–54.
   PubMed Web of Science ®Google Scholar
• Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal.[J]. Br J Surg. 1995;82(1):122–126.
   PubMed Web of Science ®Google Scholar
• Miraglia R, Pietrosi G, Maruzzelli L, et al. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma[J]. World J Gastroenterol. 2007;13(21):2952–2955.
   PubMed Web of Science ®Google Scholar
• Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal “in dysplastic nodules of the liver”. Am J Surg Pathol. 1998;22(6):656–662.
   PubMed Web of Science ®Google Scholar
• Stuart K. Chemoembolization in the management of liver tumors[J]. Oncologist. 2003;10(02):425–437.
   Google Scholar
• Osuga K, Maeda N, Higashihara H, et al. Current status of embolic agents for liver tumor embolization[J]. Int J Clin Oncol. 2012;17(4):306–315.
   PubMed Web of Science ®Google Scholar
• Tam KY, Leung CF, Wang YXJ. Chemoembolization agents for cancer treatment[J]. Eur J Pharm Sci. 2011;44(1–2):1–10.
   PubMed Web of Science ®Google Scholar
• Guan YS, Hu Y, Liu Y. Multidetector-row computed tomography in the management of hepatocellular carcinoma with transcatheter arterial chemoembolization.[J]. J Gastroenterol Hepatol. 2006;21(6):941–946.
   PubMed Web of Science ®Google Scholar